Entrectinib - Ignyta

Drug Profile

Entrectinib - Ignyta

Alternative Names: NMS-E628; RG 6268; RXDX-101

Latest Information Update: 31 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Ignyta; Nerviano Medical Sciences
  • Class Antineoplastics; Benzamides; Indazoles; Piperazines; Pyrans; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1-protein-inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Colorectal cancer; Non-small cell lung cancer; Solid tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Solid tumours
  • Phase II Colorectal cancer
  • Phase I Neuroblastoma
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 27 Jul 2018 Phase-III clinical trials in Solid tumours and Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (PO) (Chugai Pharmaceuticals Pipeline, July 2018)
  • 17 Jul 2018 Entrectinib is licensed to Chugai Pharmaceutical in Japan
  • 17 Jul 2018 Entrectinib receives Sakigake Designation in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top